Quantum BioPharma Ltd. (QNTM)
NASDAQ: QNTM · Real-Time Price · USD
23.25
-1.08 (-4.44%)
At close: Aug 13, 2025, 4:00 PM
23.40
+0.15 (0.65%)
Pre-market: Aug 14, 2025, 8:55 AM EDT
Quantum BioPharma Employees
Quantum BioPharma had 17 employees as of December 31, 2022. The number of employees increased by 7 or 70.00% compared to the previous year.
Employees
17
Change (1Y)
7
Growth (1Y)
70.00%
Revenue / Employee
n/a
Profits / Employee
-$1,589,248
Market Cap
87.31M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 17 | 7 | 70.00% |
| Dec 31, 2021 | 10 | 1 | 11.11% |
| Dec 31, 2020 | 9 | -9 | -50.00% |
| Dec 31, 2019 | 18 | -1 | -5.26% |
| Dec 31, 2018 | 19 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
QNTM News
- 2 days ago - Quantum BioPharma Announces Update to Previously Announced Private Placement - Newsfile Corp
- 3 days ago - Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial - GlobeNewsWire
- 6 days ago - Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients - GlobeNewsWire
- 7 days ago - Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt - GlobeNewsWire
- 9 days ago - Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS) - GlobeNewsWire
- 10 days ago - Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing - GlobeNewsWire
- 14 days ago - Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO - GlobeNewsWire
- 14 days ago - Quantum BioPharma Shares' Rollercoaster Day: What's Going On? - Benzinga